At Supplement Regulation Table, Industry And FDA Target Dealing Out 'Quick Buck' Players
This article was originally published in The Rose Sheet
FDA's ODSP, says Director Steven Tave, found "how much there is in common between what our goals are at FDA and what your goals are in the industry." Trade group executives suggest changes both for the industry and FDA, though none expect noncompliant firms to fall into line short of being forced off the market.
You may also be interested in...
American Pure Whey says on its website, "we are temporarily discontinuing the sale of products. Please check back in 7 days and you will be able to order our products." But firm previously warned by FDA about GMP deficiencies might want to recalculate how long sales will be stopped due to 41-count indictment on criminal charges.
CRN-organized Supplement OWL launches with nearly 2,600 labels included and adds almost 500 more in its first week, though a much larger total is needed to offer drug store chains and other retailers access a broader perspective of products available in the US.
ANSI-approved, consensus-based standards for supplement GMPs set to debut in early 2017 should help reduce the overall number of audits required for the category, says the Global Retailer and Manufacturer Alliance, which has worked since 2014 to develop the standard.